by sna1l on 12/10/20, 10:46 PM with 1 comments
by Exmoor on 12/10/20, 11:00 PM
> Following the advisory committee meeting, FDA’s career professional staff will consider the input of the advisory committee members and continue their evaluation of the submission to determine whether the available safety and effectiveness and manufacturing data support an emergency use authorization of the specific COVID-19 vaccine in the United States.
https://www.fda.gov/vaccines-blood-biologics/vaccines/emerge...